Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-01-10

Last Posted Date: 2017-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 11

Registration Number: NCT01507311

Locations: 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark

Safety and Tolerability of Liraglutide in Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-01-10

Last Posted Date: 2017-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT01507272

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2012-01-10

Last Posted Date: 2014-12-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01507389

Diabetes Attitudes Wishes and Needs

Completed

Conditions: Healthcare Professionals
Diabetes Mellitus, Type 1
Diabetes
Relatives to/Carers of Patients
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2012-01-10

Last Posted Date: 2017-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 8985

Registration Number: NCT01507116

Locations: 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom

Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries

Completed

Conditions: Haemophilia A
Haemophilia B With Inhibitors
Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B

Interventions: Other: No treatment given

First Posted Date: 2012-01-04

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 282

Registration Number: NCT01503567

Locations: 🇿🇦
Novo Nordisk Investigational Site, Sandton, South Africa

Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis

Phase 1

Completed

Conditions: Chronic Kidney Disease
End-Stage Renal Disease
Healthy

Interventions: Drug: somatropin

First Posted Date: 2011-12-30

Last Posted Date: 2017-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT01502137

Locations: 🇩🇪
Novo Nordisk Investigational Site, München, Germany

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

Phase 3

Completed

Conditions: Growth Hormone Disorder
Growth Hormone Deficiency in Children

Interventions: Drug: somatropin

First Posted Date: 2011-12-30

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 78

Registration Number: NCT01502124

Locations: 🇺🇸
Novo Nordisk Investigational Site, Seattle, Washington, United States

Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™

Completed

Conditions: Growth Hormone Disorder
Growth Hormone Deficiency in Children
Delivery Systems

Interventions: Device: NordiFlex PenMate™

First Posted Date: 2011-12-28

Last Posted Date: 2016-11-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 84

Registration Number: NCT01500486

Locations: 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden

Observational Study of NovoNorm® in Subjects With Diabetes

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide

First Posted Date: 2011-12-26

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 5841

Registration Number: NCT01498913

Locations: 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of

Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin detemir

First Posted Date: 2011-12-26

Last Posted Date: 2016-10-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 20

Registration Number: NCT01498939

Locations: 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy